Venetoclax Alone or as Combination Therapy for CLL


Venetoclax Alone or as Combination Therapy for CLL
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Jeff Sharman, MD (2/9/16)

Stilgenbauer S et al. Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: Results of the pivotal international Phase 2 study. Proc ASH 2015;Abstract LBA-6.

Salles GA et al. Updated safety and preliminary efficacy data from a Phase 1b study combining venetoclax (GDC-0199, ABT-199) with bendamustine/rituximab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Proc ASH 2015;Abstract 829.

Ma S et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Results from a Phase 1b study. Proc ASH 2015;Abstract 830.

Flinn IW et al. Safety and efficacy of a combination of venetoclax (GDC-0199/ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia — Results from a Phase 1b study (GP28331). Proc ASH 2015;Abstract 494.

Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.